Answers are grounded in this paper and cite their sources.
Preclinical study reveals Ginsenoside Ro alleviates cognitive impairment and neuroinflammation in APP/PS1 mice, suggesting a viable therapeutic mechanism for Alzheimer's disease.
These findings provide strong evidence supporting Ginsenoside Ro as a potential therapeutic agent for Alzheimer's disease. Its effects appear to be mediated through the modulation of the IBA1/GFAP-MAPK pathway, which may offer new insights into AD treatment strategies.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: